mAbxience is a biopharmaceutical company specializing in the development and commercialization of biologics, particularly biosimilars. With over a decade of experience, the company has successfully launched two biosimilar medicines for oncology—MB01 (rituximab) and MB02 (bevacizumab)—which have significantly improved patient access to treatments globally. Their development process adheres to a strict "quality by design" standard, utilizing advanced innovations in upstream and downstream processes, as well as cutting-edge analytics. mAbxience ensures that all biosimilars are equivalent in quality, safety, and efficacy to their reference products through rigorous comparability testing and clinical trials, all regulated by competent authorities.

The company boasts a robust in-house research and development platform that enhances its capabilities in biopharmaceutical development. This includes expertise in cell line development, formulation, and manufacturing processes for both drug substance (DS) and drug product (DP). mAbxience's strong internal intellectual property and regulatory teams facilitate smooth operations throughout the development stages, ensuring compliance with global regulatory standards. Additionally, the company has established strategic partnerships that extend its reach to over 100 markets worldwide, allowing it to adapt to various regulatory and commercial environments while maintaining a commitment to providing affordable, high-quality medicines.

Spain

mAbxience is a high growth international biotechnology company specialized in the research, development, manufacture and global commercialization of biopharmaceutical products to treat and prevent diseases across different therapeutic areas.

mAbxience

Company Details